Martin KJ et al. – The heterogeneity of Chronic kidney disease–mineral and bone disorder (CKD–MBD) makes strict protocol–driven therapeutic approaches difficult; accordingly, considerable individualized therapy is required. Using a case history, the authors explore several of the variables and difficulties involved in patient management.
- Chronic kidney disease–mineral and bone disorder (CKD–MBD) is the term used to describe the abnormalities of bone and mineral metabolism that occur in the setting of kidney disease.
- The spectrum of these abnormalities is wide, ranging from severe high–turnover bone disease on one end to marked low bone turnover bone disease on the other.
- Similarly, some patients have severe vascular calcifications while others do not, and the values for biochemistry determinations, including calcium, phosphorus, and parathyroid hormone, also may vary widely among patients.
- This variability may be influenced by such things as the chronicity of the particular kidney disease, effects of therapies such as corticosteroids on modifying the course of kidney disease, and comorbid conditions, such as diabetes, heart disease, age, and osteoporosis.